Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Francis A. Ayuk

Hamburg, HH, DE 
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Francis Ayuk practices in Hamburg, Germany. Mr. Ayuk is rated as an Experienced expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Graft Versus Host Disease (GvHD), Myelofibrosis, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 194 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Gender
Male

Locations

Hamburg, HH 20246, Germany
Other Locations
Eppendorf, HH, Germany
Munich, BY, Germany
Eppendorf, SN, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Enrollment Status: Terminated
Publish Date: December 02, 2019
Intervention Type: Drug
Study Phase: Phase 2

194 Total Publications

Remission status prior allogeneic stem cell transplantation in AML/MDS patients harboring single-hit or multi-hit p53 mutations does not impact outcome.
Remission status prior allogeneic stem cell transplantation in AML/MDS patients harboring single-hit or multi-hit p53 mutations does not impact outcome.
Journal: Transplantation and cellular therapy
Published: August 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ayuk's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile